RRM2

Across TCGA pan-cancer cohorts, RRM2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RRM2 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RRM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RRM2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

ACC, UCEC, and COAD are the cancer types where RRM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.034	12	view →
COAD	DFS	Median	All	0.140	0.781	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	0.670	0.325	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RRM2–ACC (OS)

Open the ACC breakdown →